Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 878 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer, Rectum Clear all
Completed Phase 1 Interventional Results available

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017
View directory record Official record
Conditions
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions
ELI-002 2P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Chemoradiation or Brachytherapy for Rectal Cancer

NCT02017704
View directory record Official record
Conditions
Rectal Cancer
Interventions
Endo-HDR (if randomized to this arm), capecitabine and IMRT (if randomized to this arm), IMRT (intensity modulated radiation therapy), FOLFOX6, Surgery
Radiation · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
4
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 21, 2026, 9:41 AM EDT
Not listed Phase 1 Interventional

Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer

NCT00021268
View directory record Official record
Conditions
Colorectal Cancer
Interventions
tocladesine
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Assessing Effect of Withdrawal Time on Adenoma Detection Rate for Screening Colonoscopy

NCT05018325
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Colorectal Cancer
Interventions
Colonoscopy with 6 minute withdrawal, Colonoscopy 9 minute withdrawal, Colonoscopy 12 minute withdrawal
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated Not applicable Interventional Results available

Radial Reload Open LAR Case Series

NCT01717014
View directory record Official record
Conditions
Low Anterior Resection, Proctosigmoid Resection, Rectal Cancer
Interventions
Covidien Radial Reload Stapler with Tri-Staple Technology
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Tampa, Florida • Durham, North Carolina • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 21, 2026, 9:41 AM EDT
Withdrawn Not applicable Interventional

Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients

NCT02112240
View directory record Official record
Conditions
Rectal Cancer
Interventions
Intraoperative Mobile Gamma Camera imaging, Endoscopic injection of 99mTc-sulfur colloid, Endoscopic injections of Spot, Preoperative flexible sigmoidoscopy, SPECT/CT
Other · Drug · Procedure + 1 more
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer

NCT00468910
View directory record Official record
Conditions
Colon Cancer, Precancerous Condition, Rectal Cancer
Interventions
acetylsalicylic acid, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer

NCT00003344
View directory record Official record
Conditions
Colorectal Cancer
Interventions
irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 21, 2026, 9:41 AM EDT
Completed No phase listed Observational

Prospective Assessment of Symptoms and Quality of Life in Rectal Cancer Patients Receiving Chemo-Radiotherapy

NCT00414232
View directory record Official record
Conditions
Rectal Cancer
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

NCT00022698
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Capecitabine, Irinotecan
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
17
States / cities
Birmingham, Alabama • Loma Linda, California • Norwich, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

NCT03667716
View directory record Official record
Conditions
Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer
Interventions
COM701, COM701 with Opdivo (Nivolumab).
Drug
Lead sponsor
Compugen Ltd
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Sarasota, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

NCT00335504
View directory record Official record
Conditions
Colon Cancer, Precancerous Condition, Rectal Cancer
Interventions
oligofructose-enriched inulin, sulindac, placebo, atorvastatin calcium, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting Phase 1 Interventional

Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial

NCT06834126
View directory record Official record
Conditions
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Consolidation Therapy, Functional Magnetic Resonance Imaging, Gastrointestinal Endoscopy, Magnetic Resonance Imaging, Papaverine, Radiation Therapy, Total Mesorectal Excision
Procedure · Drug · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 21, 2026, 9:41 AM EDT
Not listed Phase 2 Interventional

Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer

NCT00967655
View directory record Official record
Conditions
Colorectal Cancer
Interventions
panitumumab, capecitabine, irinotecan hydrochloride, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Loma Linda Oncology Medical Group, Inc.
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
4
States / cities
Redlands, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 21, 2026, 9:41 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958
View directory record Official record
Conditions
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Interventions
MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen
Drug · Biological
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
185
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

NCT02574663
View directory record Official record
Conditions
Pancreatic Cancer, Colorectal Cancer, Rectal Cancer, Gastric Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST)
Interventions
TGR-1202, nab-paclitaxel + gemcitabine, Oxaliplatin + Folinic acid + Fluorouracil, Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Not applicable Interventional

Home-based HIIT to Improve CRC Survivorship: Feasibility and Relationship With Novel Surrogate Biomarkers of CRC Recurrence

NCT04080414
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colonic Neoplasms, Colonic Cancer, Rectal Neoplasms, Rectal Cancer
Interventions
Home-based high-intensity interval training, Home-based moderate-intensity continuous exercise
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
19 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer

NCT01376453
View directory record Official record
Conditions
Rectal Cancer
Interventions
Sorafenib, 5-Fluorouracil (5-FU), Radiation
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting Not applicable Interventional

Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)

NCT06380101
View directory record Official record
Conditions
Rectal Cancer
Interventions
NEAAR Medical Food
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated Not applicable Interventional Results available

SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study

NCT05010850
View directory record Official record
Conditions
Colorectal Cancer, Rectal Cancer, Rectal Tumor, Rectal/Anal
Interventions
Colovac, Stoma Creation
Device · Procedure
Lead sponsor
SafeHeal Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Worcester, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 21, 2026, 9:41 AM EDT
Active, not recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions
Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1405
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Selenium for Prevention of Adenomatous Colorectal Polyps

NCT00078897
View directory record Official record
Conditions
Colorectal Cancer, Adenomatous Colorectal Polyps, Precancerous Condition
Interventions
Selenium
Drug
Lead sponsor
University of Arizona
Other
Eligibility
40 Years to 80 Years
Enrollment
1,621 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
7
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 1Phase 2 Interventional

SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer

NCT00005818
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
irinotecan hydrochloride, semaxanib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 21, 2026, 9:41 AM EDT